ArticleBMC surgery2025
Evaluation of monocyte distribution width as a predictive factor for early complications of pancreatic surgery (pancreaticoduodenectomy): a retrospective cohort study.
Article in BMC surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aim of this study was to evaluate the clinical utility of the monocyte distribution width (MDW) as an early diagnostic biomarker for detecting postoperative complications in pancreatic surgery patients. Complications from pancreatic surgery, particularly pancreatic fistulas, significantly reduce patient survival rates. Compared with conventional markers, changes in the MDW may be detected earlier, facilitating timely intervention and potentially improving patient outcomes.
methodsThe MDW, C-reactive protein (CRP) level, and white blood cell (WBC) count were measured preoperatively and on postoperative days 1, 3, and 7. Complications-including clinically relevant pancreatic fistulas (CR-POPF) and anastomotic leaks-were classified using standardized criteria. Statistical analysis involved ROC curves and multivariate modelling to assess diagnostic accuracy and independent predictors. This retrospective analysis of a prospectively collected cohort included 82 patients who underwent elective pancreaticoduodenectomy (PD) for cancer at a single centre between May 2021 and March 2024.
resultsIn this cohort of 82 patients with prospective data collection and retrospective analysis who underwent PD, the MDW emerged as a significant early predictor of postoperative complications. On postoperative day 3, the MDW was independently associated with CR-POPF (AUC 0.781; OR 1.31, p = 0.044) and anastomotic leaks (ΔMDW days 0-3: OR 1.30, p = 0.015). Compared with conventional markers, the MDW demonstrated superior diagnostic performance, with ROC AUC values ranging from 0.770 to 0.818 across different complications. A day 3 cut-off value of > 23.1 showed high sensitivity (84%) and yielded positive likelihood ratios of up to 3.7. Furthermore, the MDW on day 3 was moderately to strongly correlated with subsequent inflammatory markers, such as the CRP level, on day 7 (r = 0.468, p < 0.001). Multivariate models confirmed the independent prognostic value of the MDW for predicting overall complications, anastomotic leaks, and CR-POPF.
conclusionCompared with the CRP level and WBC count, the MDW demonstrated superior and earlier predictive ability for detecting postoperative complications. Its elevation by day 3 provided early warning, especially for CR-POPF and leaks. As a rapid, cost-effective marker available from routine blood counts, the MDW may enhance postoperative monitoring and guide timely intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.